The Korean Herald reported today that Celltrion has applied for the European Medicine Agency’s approval of CT-P17, a Humira (adaliumumab) biosimilar.  According to the Korean Herald, Celltrion “expects to introduce CT-P17 to the European market in about a year’s time, which is how long the EMA typically takes to review.”  The article reports that, “[d]ue to its high potency, CT-P17 can have its targeted effect with less amount of injection than the original” and that CT-P17 “is citrate-free, meaning it causes less pain upon injection.”